ResMed Inc. (RMD) Expected to Announce Earnings of $0.75 Per Share

Equities research analysts predict that ResMed Inc. (NYSE:RMD) will announce $0.75 earnings per share (EPS) for the current fiscal quarter, according to Zacks Investment Research. Two analysts have issued estimates for ResMed’s earnings. The lowest EPS estimate is $0.70 and the highest is $0.76. ResMed reported earnings per share of $0.74 during the same quarter last year, which indicates a positive year over year growth rate of 1.4%. The firm is scheduled to report its next quarterly earnings results after the market closes on Tuesday, August 1st.

On average, analysts expect that ResMed will report full-year earnings of $2.80 per share for the current financial year, with EPS estimates ranging from $2.76 to $2.83. For the next financial year, analysts forecast that the business will post earnings of $3.12 per share, with EPS estimates ranging from $2.93 to $3.33. Zacks Investment Research’s earnings per share averages are a mean average based on a survey of research analysts that that provide coverage for ResMed.

ResMed (NYSE:RMD) last released its earnings results on Thursday, April 27th. The medical equipment provider reported $0.71 EPS for the quarter, topping analysts’ consensus estimates of $0.70 by $0.01. The company had revenue of $514.20 million during the quarter, compared to analysts’ expectations of $525.84 million. ResMed had a net margin of 15.96% and a return on equity of 22.53%. ResMed’s revenue for the quarter was up 13.3% on a year-over-year basis. During the same period last year, the business earned $0.68 EPS.

RMD has been the topic of several analyst reports. BidaskClub upgraded ResMed from a “buy” rating to a “strong-buy” rating in a report on Saturday, June 17th. Zacks Investment Research downgraded ResMed from a “buy” rating to a “hold” rating in a report on Tuesday, March 28th. Citigroup Inc. downgraded ResMed from a “buy” rating to a “neutral” rating in a report on Friday, April 28th. William Blair reiterated an “outperform” rating on shares of ResMed in a report on Thursday, April 13th. Finally, Jefferies Group LLC reiterated a “sell” rating and set a $56.00 target price on shares of ResMed in a report on Friday, April 28th. Four investment analysts have rated the stock with a sell rating, four have assigned a hold rating, three have given a buy rating and one has issued a strong buy rating to the company’s stock. ResMed currently has a consensus rating of “Hold” and an average target price of $64.50.

ResMed (RMD) remained flat at $76.82 during mid-day trading on Wednesday. The company had a trading volume of 646,157 shares. The stock’s 50-day moving average price is $72.98 and its 200-day moving average price is $69.45. ResMed has a 52 week low of $56.59 and a 52 week high of $79.44. The firm has a market capitalization of $10.89 billion, a price-to-earnings ratio of 33.69 and a beta of 0.84.

The firm also recently disclosed a quarterly dividend, which was paid on Thursday, June 15th. Shareholders of record on Thursday, May 11th were issued a dividend of $0.33 per share. The ex-dividend date was Tuesday, May 9th. This represents a $1.32 annualized dividend and a yield of 1.72%. ResMed’s dividend payout ratio is presently 57.64%.

In other news, insider James Hollingshead sold 7,139 shares of the business’s stock in a transaction that occurred on Monday, April 17th. The stock was sold at an average price of $68.37, for a total value of $488,093.43. Following the completion of the sale, the insider now directly owns 44,934 shares in the company, valued at approximately $3,072,137.58. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Jr. Gregor K. Emmert purchased 424,000 shares of the stock in a transaction dated Wednesday, June 28th. The stock was purchased at an average price of $0.06 per share, with a total value of $25,440.00. Insiders have sold a total of 180,260 shares of company stock worth $13,495,616 over the last 90 days. 1.97% of the stock is owned by company insiders.

Several large investors have recently modified their holdings of the stock. Commerzbank Aktiengesellschaft FI increased its stake in shares of ResMed by 0.3% in the first quarter. Commerzbank Aktiengesellschaft FI now owns 5,238 shares of the medical equipment provider’s stock worth $377,000 after buying an additional 14 shares during the period. Morgan Dempsey Capital Management LLC increased its stake in shares of ResMed by 2.3% in the first quarter. Morgan Dempsey Capital Management LLC now owns 2,189 shares of the medical equipment provider’s stock worth $158,000 after buying an additional 50 shares during the period. Intrust Bank NA increased its stake in shares of ResMed by 1.0% in the first quarter. Intrust Bank NA now owns 7,101 shares of the medical equipment provider’s stock worth $511,000 after buying an additional 73 shares during the period. Pacer Advisors Inc. increased its stake in shares of ResMed by 3.0% in the first quarter. Pacer Advisors Inc. now owns 2,699 shares of the medical equipment provider’s stock worth $194,000 after buying an additional 79 shares during the period. Finally, Atria Investments LLC increased its stake in shares of ResMed by 1.9% in the first quarter. Atria Investments LLC now owns 4,564 shares of the medical equipment provider’s stock worth $328,000 after buying an additional 83 shares during the period. Institutional investors and hedge funds own 60.75% of the company’s stock.

TRADEMARK VIOLATION WARNING: This piece of content was originally posted by WKRB News and is owned by of WKRB News. If you are reading this piece of content on another website, it was copied illegally and republished in violation of international copyright and trademark legislation. The original version of this piece of content can be accessed at https://www.wkrb13.com/markets/2286395/resmed-inc-rmd-expected-to-announce-earnings-of-0-75-per-share.html.

ResMed Company Profile

ResMed Inc is a holding company. The Company is engaged in the development, manufacturing, distribution and marketing of medical devices and cloud-based software applications that diagnose, treat and manage respiratory disorders, including sleep disordered breathing (SDB), chronic obstructive pulmonary disease (COPD), neuromuscular disease and other diseases.

Get a free copy of the Zacks research report on ResMed (RMD)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for ResMed (NYSE:RMD)

This story was originally published by WKRB News (https://www.wkrb13.com) and is the sole property of WKRB News. If you are reading this article on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. You can view the original version of this story at https://www.wkrb13.com/markets/2286395/resmed-inc-rmd-expected-to-announce-earnings-of-0-75-per-share.html

Receive News & Ratings for ResMed Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ResMed Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

 


Leave a Reply

 
© 2006-2017 WKRB News.